Actuate Therapeutics, Inc. ACTU
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.98% | 39.94% | 88.19% | 173.26% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.46% | -8.07% | -10.59% | -7.06% | -- |
| Operating Income | 14.46% | 8.07% | 10.59% | 7.06% | -- |
| Income Before Tax | 17.14% | 14.90% | 18.54% | 15.22% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 17.14% | 14.90% | 18.54% | 15.22% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17.14% | 14.90% | 18.54% | 15.22% | -- |
| EBIT | 14.46% | 8.07% | 10.59% | 7.06% | -- |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 41.14% | 81.72% | 89.77% | 92.05% | -- |
| Normalized Basic EPS | 36.49% | 79.06% | 88.67% | 91.49% | -- |
| EPS Diluted | 41.14% | 81.72% | 89.77% | 92.05% | -- |
| Normalized Diluted EPS | 36.49% | 79.06% | 88.67% | 91.49% | -- |
| Average Basic Shares Outstanding | 32.92% | 71.46% | 151.52% | 420.83% | -- |
| Average Diluted Shares Outstanding | 32.92% | 71.46% | 151.52% | 420.83% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |